Biagini Giancarlo A, O'Neill Paul M, Bray Patrick G, Ward Stephen A
Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.
Curr Opin Pharmacol. 2005 Oct;5(5):473-8. doi: 10.1016/j.coph.2005.05.004.
In response to the emergence of parasite drug resistance to currently deployed antimalarials, the scientific community, in partnership with the pharmaceutical industry and public organizations, has fashioned an antimalarial drug development portfolio for the sustained development and registration of safe, effective and cheap antimalarial medicines. The management of this portfolio is being driven by MMV (Medicines for Malaria Venture), with a number of projects recently reaching the clinical end of this drug development pipeline.
针对目前使用的抗疟药物出现寄生虫耐药性的情况，科学界与制药行业及公共组织合作，制定了一个抗疟药物开发项目组合，以持续开发和注册安全、有效且廉价的抗疟药物。该项目组合的管理由疟疾药物事业（MMV）推动，最近有多个项目已进入这一药物开发流程的临床阶段。
